A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
In this trial, patients with mantle cell lymphoma will be included, treatment with
lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12
cycles, cycle length 28 days. Patients with complete remission, partial response or stable
disease will enter a maintenance phase with treatment with ibrutinib and rituximab until
progression of disease.
The primary objective is to evaluate overall response rate, based on PET and CT.